21/07/18

Clinical Trial Maxiliv

Tags

Clinical Trial Maxiliv
Result Seeding trial Maxiliv (Phosphatidylcholine, Schizandrae powder extract, Silymarin, Alpha-lipoic acid) in Liver Damage Patient
Conducted by dr. Johannes V. Lucida Sp.PD
RS. Delta Surya, Sidoarjo, Surabaya
Objectives:
Memperoleh hasil dari pemakain MAXILIV, dengan kombinasi formula maxiliv (Phosphatidylcholine, Schisandra Powder extract, Silymarin, Alpha-lipoic acid in Liver Damage Patient.

Method:
  • Patients Diagnosis of chronic hepatitis was confirmed by abnormality of transferase enzymes (>1,5 UNL) for enzymes more than 6 months more
  • On admission: SGOT, SGPT, HBsAg, Anti HCV, US, bilirubin, total protein, albumin, PT (INR)
  • At the end of study, reexamination was performed, with assesment of SGOT, SGPT, GGT, total bilirubin, direct bilirubinm indirect bilirubin,
  • Patient was treated Maxiliv (Lecithin 715 mg, Providing phosphatydilcoline 250 mg, Schzandrae powder Extract 50 mg, Silymarin 70 mg) one times daily, orally, for 4 weeks
  • Examination 5 patients with dose 1x1 for 4 weeks before and after treatment
Variable
Pre Theraphy
Post Therapy
Unit
SGPT
99
63
U/L
SGOT
114
91
U/L
Total Bilirubin
0.61
0.49
mg/dl
Bilirubin Direct
0.21
0.18
mg/dl
Gamma GT
3735U/L
Conclusion;
Berdasarkan hasil trial tersebut, diperoleh penurunan kadar SGPT, SGOT, Gamma GT dan bilirubin dalam pemakaian maxiliv selama 4 minggu dengan dosis hanya 1x1 hari. Hal ini menunjukan adanya penurunan aktifitas inflamasi pada hati yang menderita hepatitis tersebut. Kandungan silymarin dan schisandrae yang terdapat dalam maxiliv mampu memberikan aktifitas dan inflamasi pada sel hati yang mengalami kerusakan.

Result Seeding trial Maxiliv (Phosphatidylcholine, Schizandrae powder extract, Silymarin, Alpha-lipoic acid) in patients with pulmonary tuberculosis
conducted by dr.Septa Ekanita Sp.P
RS.Paru palembang & RS. siti Khadijah Palembang

Objectives:
Memperoleh hasil dari pemakaian MAXILIV, dengan kombinasi Formula Maxiliv (Phosphatidylcholine, Schisandra Powder extract, Silymarin, Alpha-lipoic acid in Liver Damage Patient.

Method:
Seeding trial diberikan pada 3 pasien dengan type penyakit yang diderita oleh pasien adalah Tuberculosis (TB). Pasien diberikan maxiliv selama 4 minggu dengan dosis hanya 2x1 hari.
penggunaan hepatoprotektor yang diberikan adalah tanpa kombinasi dengan hepatoprotektor lain, sehingga murni MAXILIV yang diberikan kepada pasien.

Conclusion:
Berdasarkan hasil trial tersebut, diperoleh penurunan kadar SPGT & SGOT yang signifikan, mempercepat masa pemyembuhan, memperbaiki nafsu makan, mengurangi gejala mual dan muntah, dan terjadi peningkatan kadar albumin dan globulin dalam pemakaian maxiliv selama 4 mingggu dengan dosis 2x1 perhari. Perbaikan ini menunjukan bahwa pemberian maxiliv mampu memberikan perbaikan pada kerusakan hati pasien tanpa diberikan lagi sediaan hepatoprotektor lainnya.

IN PROCESS CLINICAL TRIAL OF MAXILIV AS HEPATOPROTECTOR USING FOR HEPATITIS B, CHRONIC HEPATITIS C AND NAFLD PATIENTS

Conducted by DR.dr. Rino Alvani Gani, Spd.PD-KGEH,FINASIM
Rs. Dr.Cipto Mangunkusumo, Jakarta

Background and Aims: Hepatitis B, Chronic Hepatitis c, and Nonalcholic fatty liver disease (NAFLD) is a chronic liver condition that is characterized by significant hepatic lipid deposition with our without necroinflamation and fibrosis. Researhers have proposed that oxidative stress may play a role in pathogenesis of its treatment. Therefore, we tried MAXILIV as an antioxidant in a randomized controlled trial for a group of patients with Hepatitis B, Chronic Hepatitis C, and NAFLD.

Methods: During a four month period, a placebo-controlled study was conducted among patients with Hepatitis B, Chronic Hepatitis C, and Nonalcoholic Fatty Liver Disease (NAFLD)
Referred to division of Hepatology, Departement Of Internal Medicine, Faculty Of Medicine, University of Indonesia/ Dr. Cipto Mangunkusumo General Hospital. Based on sonography findings and elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels or liver biopsy , we selected 60 patients who where referred to our center for management of liver disease. Besides, the study was conducted also by using FibroScan, to view the structure of liver tissue repair. Patients who excluded from the study. Patients who had positive viral markers nd other hepatic diseases and patients who had ingested ethanol or drugs known to produce fatty liver disease within the previous 4 months were excluded from the study. Patients were randomized to two group ; Group A, 30 patients received a placebo, and Group B, 30 patients received treatment with Maxiliv, twice a day. Treatment was continued for 4 months, adn cases were evaluated every 4 weeks in the hepatology clinic.


EmoticonEmoticon